Scientific Officer / VP Business Development Europe BioAgilytix Labs Overland Park, Kansas
Significant efforts are spent in the biopharmaceutical industry to execute translational pharmacology strategies aiming to reduce costly compound attrition in phase 2 clinical trials. A key element is to develop a deep understanding of the properties of human drug targets early on in discovery phases as well as to predict and measure how targets are engaged by biotherapeutics. This leads to selection of better targets, improved prediction of the PK/PD relationship and clinical dosing regimen. To this end, the biopharmaceutical industry has been applying quantitative protein mass spectrometry for over a decade now, enabling protein biomarker and target measurements previously considered unattainable. However, the biomarker mass spectrometry field is continuing its evolution at a rapid pace. The next horizon is already here: protein kinetics measurement, transgene protein expression analysis for gene therapy and the pursuit of protein biomarker in extracellular vesicles in the context of liquid biopsy are just a few of the exciting new areas in need of technical solutions. What workflows are needed to address these emerging questions? Is your protein biomarker mass spectrometry lab ready for the next horizon? Using case studies this presentation will illustrate how next horizon challenges can be tackled. Furthermore, this presentation will share our future vision for quantitative protein biomarker mass spectrometry in biopharmaceutical research.
discuss the opportunities ahead for protein biomarker mass spectrometry and what it is needed to address emerging project challenges
identify new areas of impact using protein mass spectrometry
understand workflow and technology options to measure target engagement of biologics, protein kinetics , transgene protein expression for gene therapy and pursue protein biomarkers in extracellular vesicles in the context of liquid biopsy